Welcome to our dedicated page for Cambiar Aggressive Value ETF news (Ticker: CAMX), a resource for investors and traders seeking the latest updates and insights on Cambiar Aggressive Value ETF stock.
Camurus (CAMX) develops and commercializes long-acting medicines for severe and chronic diseases using its proprietary FluidCrystal® technology. Recurring news covers endocrine, dependence, pain, cancer and cardiometabolic programs, including Oczyesa®/CAM2029 octreotide depot for acromegaly and CAM2056, a monthly subcutaneous semaglutide formulation.
Company updates also include clinical-study results, regulatory submissions and authorizations, product-launch activity, and collaboration or license agreements tied to long-acting injectable therapies. Camurus reports operations across Europe, the United States and Australia, with shares listed on Nasdaq Stockholm under the ticker CAMX.
Summary not available.
Cambiar Investors announces the launch of the Cambiar Aggressive Value ETF (NYSE Arca: CAMX), transitioning from the Cambiar Aggressive Value Fund. This actively managed ETF focuses on a concentrated portfolio of 20-30 high-conviction stocks, aiming for strong absolute returns and referencing the Russell 1000 Value Index. Cambiar President Brian Barish highlights value investing's resurgence, correlating with the higher cost of capital and growth stock performance challenges. Investors may find CAMX appealing as market leadership shifts towards value.